文献速递妇科生殖医学

抗苗勒管激素在不同诊断标准下用于非选择人群多囊卵巢综合征诊断的价值

Anti-Müllerian hormone as a diagnostic tool for PCOS under different diagnostic criteria in an unselected population.
PubMed 文献 · Reprod Biomed Online · 2019-04-10

本研究在非选择女性人群(n=392份冻存血清)中评估抗苗勒管激素(AMH)按NIH、Rotterdam-2003和AE-PCOS标准诊断多囊卵巢综合征(PCOS)的效能。年龄和体质指数校正后AUC分别为0.80(95%CI 0.71-0.89)、0.74(0.67-0.81)和0.71(0.64-0.79);表型A患者aAUC为0.85(0.77-0.92),其余表型诊断效能差至中等。结论认为除具备全部特征的A表型外,AMH诊断PCOS的效度差至中等。

要点

  • 非选择人群中AMH诊断PCOS的校正AUC按NIH、Rotterdam-2003、AE-PCOS标准分别为0.80、0.74、0.71。
  • 将PCOM定义改为AFC≥20后,Rotterdam-2003和AE-PCOS标准下患病率分别从19.9%降至10.2%、从15.3%降至8.9%。
  • 表型A患者AMH诊断aAUC为0.85(0.77-0.92);表型B、C、D诊断效能差至中等。

核心结论

  • 在非选择女性人群中,除具备全部特征的A表型外,AMH诊断PCOS的效度差至中等;该结论在NIH、Rotterdam-2003和AE-PCOS标准下以及将PCOM改为AFC≥20后均成立。

研究设计与样本

  • 横断面研究,使用既往PCOS患病率研究采集的冻存血清样本(n=392)检测AMH浓度。
  • 以NIH、Rotterdam-2003和AE-PCOS标准分别评估AMH诊断PCOS的效能。

主要发现

  • 年龄和体质指数校正后AUC(95%CI)按NIH、Rotterdam-2003、AE-PCOS标准分别为0.80(0.71-0.89)、0.74(0.67-0.81)、0.71(0.64-0.79)。
  • 将PCOM定义为AFC≥20而非12后,按Rotterdam-2003标准患病率从19.9%降至10.2%,按AE-PCOS标准从15.3%降至8.9%。
  • 表型A(高雄激素血症、排卵功能障碍和PCOM)患者中AMH诊断的aAUC为0.85(0.77-0.92)。
  • 表型B(高雄激素血症+排卵功能障碍)、C(高雄激素血症+PCOM)或D(排卵功能障碍+PCOM)中AMH诊断效能差至中等。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

RESEARCH QUESTION: Is anti-Müllerian hormone (AMH) a valid tool to diagnose polycystic ovary syndrome (PCOS) according to different subsets of criteria among an unselected group of women? DESIGN: In this cross-sectional study, AMH concentrations were measured in an unselected group of women. The ability of AMH to diagnose PCOS according to National Institutes of Health (NIH), Rotterdam-2003 and Androgen Excess and PCOS Society (AE-PCOS) criteria was tested by using frozen serum aliquots (n = 392) that had been collected from a previous prevalence study of PCOS. RESULTS: The respective age and body mass index adjusted area under the curve (aAUC, 95% confidence interval) values were 0.80 (0.71-0.89), 0.74 (0.67-0.81) and 0.71 (0.64-0.79). When the definition of polycystic ovary morphology (PCOM) was set to an antral follicle count (AFC) of 20 instead of 12, the prevalence of syndrome dropped from 19.9% to 10.2% and from 15.3% to 8.9% according to Rotterdam-2003 and AE-PCOS criteria, respectively. In patients with Phenotype A, who had hyperandrogenism, ovulatory dysfunction and PCOM, AMH had an aAUC of 0.85 (0.77-0.92) to diagnose the syndrome. In Phenotypes B (hyperandrogenism + ovulatory dysfunction), C (hyperandrogenism + PCOM) or D (ovulatory dysfunction + PCOM), AMH had poor to fair ability to diagnose the syndrome. CONCLUSION: AMH has poor to fair validity to diagnose PCOS among an unselected group of women, except for patients bearing all features of the syndrome (Phenotype A). This finding is valid using the NIH, Rotterdam-2003 and AE-PCOS criteria and even after revising the definition of PCOM as AFC ≥20.

来源:Reprod Biomed Online,查看原文。版权归原作者所有。

引用

  1. Bozdag G, Mumusoglu S, Coskun ZY, et al. Anti-Müllerian hormone as a diagnostic tool for PCOS under different diagnostic criteria in an unselected population. Reprod Biomed Online. 2019. PMID: 31182353. doi:10.1016/j.rbmo.2019.04.002

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。